Drug Information

Drug General Information
Drug ID
D0V2QU
Former ID
DNCL002074
Drug Name
Anti-CD22/CD19 mab-toxin conjugate
Drug Type
Monoclonal antibody
Indication Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10:C91.0] Investigative [525761]
Company
Abiogen Pharma
Target and Pathway
Target(s) B-lymphocyte antigen CD19 Target Info Modulator [525761]
B-cell receptor CD22 Target Info Modulator [525761]
KEGG Pathway PI3K-Akt signaling pathway
Hematopoietic cell lineage
B cell receptor signaling pathway
Epstein-Barr virus infection
Primary immunodeficiencyhsa04514:Cell adhesion molecules (CAMs)
NetPath Pathway IL-7 Signaling Pathway
PANTHER Pathway B cell activationP00010:B cell activation
Pathway Interaction Database BCR signaling pathwaybcr_5pathway:BCR signaling pathway
Reactome PIP3 activates AKT signaling
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Constitutive Signaling by Aberrant PI3K in Cancer
Antigen activates B Cell Receptor (BCR) leading to generation of second messengersR-HSA-198933:Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
WikiPathways Human Complement System
Signaling by the B Cell Receptor (BCR)
PIP3 activates AKT signaling
B Cell Receptor Signaling Pathway
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cellWP23:B Cell Receptor Signaling Pathway
References
Ref 525761Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000 May;14(5):853-8.
Ref 525761Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000 May;14(5):853-8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.